Raynaud's Disease/Vascana Confirmatory Clinical Study Completes Patient Screening

Bothell, WA – 14 June 2010 – Today MediQuest Therapeutics, Inc., a specialty pharmaceutical company, announced the completion of patient screening for its clinical study of Vascana, a non-systemic, topical application designed to treat Raynaud’s Disease.  This clinical trial is being carried out in accordance with the Complete Response letter from the US FDA.  A total of 284 patients were screened.

 According to Dr. Frederick J. Dechow, President and CEO, they anticipate completing randomization of qualifying patients by mid-July 2010 and concluding the clinical study by mid-August 2010.

  “Vascana is the first new, potential treatment option for Raynaud’s Disease in more than 20 years. There is currently no pharmaceutical product specifically approved by the FDA for patients suffering from Raynaud’s Disease,” says Dechow.

 Of the more than nine million people suffering from Raynaud’s Disease in the U.S., 90 percent are women and over one million people require year-round medical treatment for the disease.

 “Vascana is a new therapy designed to treat an unmet clinical need,” said Dr. Jeff Gregory, Chief Medical Officer of MediQuest Therapeutics. “Our prior clinical trials have shown that the product works and that it’s well tolerated by patients.”

 About MediQuest Therapeutics, Inc.

MediQuest Therapeutics is a specialty pharmaceutical company using its proprietary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company’s major efforts are focused on projects targeting Raynaud’s phenomenon, nail psoriasis, and actinic keratosis.